all report title image
  • Published On : Sep 2022
  • Code : CMI5210
  • Industry : Pharmaceutical
  • Pages : 165
  • Formats :

For the treatment of Sjorgens’s Syndrome, sometime people manage the treatment using through OTC drug, counter eye drop and but for serious issue prescription drug or surgical procedure is needed.

People with Sjogren’s develop more severe inflammation, involving organs such as the kidneys, lungs, intestines, or brain. For these people, physician may prescribe more aggressive medications such as Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.

The global Sjogren’s syndrome market is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% over the forecast period (2022-2030).

Figure 1. Global Sjogren’s syndrome Market Share (%) in Terms of Value, by Region, 2022

Sjogren’s Syndrome  | Coherent Market Insights

Increasing robust pipeline of drug is expected to aid in the growth of the global Sjogren’s syndrome market.

Increasing robust pipeline of drug is expected to aid in the growth of the global Sjogren’s syndrome market. For instance, according to data published in July 2022, on Nation Institute of Medicine (NIH),states that a randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study is going on to assess the efficacy and safety of the drug Ianalumab in patients with  Sjogren's syndrome and the estimated study completion date is in March 2026.

CMI table icon

Sjogren’s Syndrome Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 234.6 Mn
Historical Data for: 2017 to 2021 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 3.5% 2030 Value Projection: US$ 308.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug: Antimalarial Quinolines, Cholinergic Agonists, Corticosteroids, Others (Pain Relief Medication and late phase drug)
  • By Type: Primary, Secondary
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 
Companies covered:

ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis, MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.

Growth Drivers:
  • Increasing robust pipeline of drug  for the treatment of sjogren’s syndrome
  • Increasing research and development of drug for the treatment of sjogren’s syndrome 
Restraints & Challenges:
  • Treatments currently available either only treat the symptoms or are viewed as ineffective by many patients

Figure 2. Global Sjogren’s syndrome Market Share (%), by Drug, 2022

Sjogren’s Syndrome  | Coherent Market Insights

Global Sjogren’s syndrome Market: Restraint

Many of the Sjogren’s treatments that are currently available either only treat the symptoms or are viewed as ineffective by many patients. For instance, according to data published in September 2021, on Frontiers Media Journal, in a randomized trial, hydroxychloroquine (HCQ) did not significantly reduce the symptoms of primary Sjogren’s after 24 weeks of treatment when compared to placebo. In a similar other studies came to the same conclusion that hydroxychloroquine (HCQ) is not a successful treatment for primary Sjorgens.

 Key Players

Major players operating in the global Sjogren’s syndrome market include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis/MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.

Sjogren’s syndrome is systematic autoimmune disorder which effect the entire body, along with complication such as, chronic pain, major organ involvement, profound fatigue, neuropathies and Sjogren’s syndrome zmphomas.

For the treatment of Sjogren’s syndrome different medication such as methotrexate available to manage the syndrome. Currently no single medication has been conclusively proven to treat the progression of Sjogren’s.

Antimalarial Quinolines, Cholinergic Agonists and Corticosteroids are the prescription drug used for the treatment of Sjogren’s.

Market Dynamics

Increasing prevalence of Sjogren’s syndrome is expected to drive the market growth during the forecast period.

For instance, according to the Sjogren’s Foundation 2021, around 3 to 4 million people in the U.S. suffer from Sjogren’s syndrome which is as common as rheumatoid arthritis (RA), and three times as common as systemic lupus erythematosus (SLE).

Key features of the study:

  • This report provides an in-depth analysis of the global sjogren’s syndrome market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global sjogren’s syndrome Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis/MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global sjogren’s syndrome Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sjogren’s syndrome Market

Detailed Segmentation:

  • Global Sjogren’s Syndrome Market, By Drug:
    • Antimalarial Quinolines
    • Cholinergic Agonists
    • Corticosteroids
    • Others (Pain Relief Medication and late phase drug)
  • Global Sjogren’s Syndrome Market, By Type:
    • Primary
    • Secondary
  • Global Sjogren’s Syndrome Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Sjogren’s Syndrome Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest Of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • ADVANZ Pharma *
      • Company Overview
      • Type Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Bristol Myers Squibb
    • Daiichi Sankyo
    • GlaxoSmithKline
    • Novartis/MorphoSys
    • RemeGen
    • Resolve Therapeutics
    • TearSolutions
    • VIELABIO
    • Otsuka Pharmaceutical Co., Ltd.
    • Bridge Pharma Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global Sjogren’s syndrome market size is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% between 2022 and 2030.
Increasing robust pipeline of drug is expected to aid in the growth of the market.
Antimalarial Quinolones drug segment is expected to hold the major market share in the market.
North America holds the largest market share in the market.
Many of the Sjogren’s treatments that are currently available either only treat the symptoms or are viewed as ineffective by many patients are the Major factors hampering the market growth.
Major players operating in the market include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis/MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo